PT1019068E - Formulações terapêuticas contendo veneno de serpente e/ou insecto para a profilaxia e terapia de neoplasmas - Google Patents

Formulações terapêuticas contendo veneno de serpente e/ou insecto para a profilaxia e terapia de neoplasmas Download PDF

Info

Publication number
PT1019068E
PT1019068E PT97939108T PT97939108T PT1019068E PT 1019068 E PT1019068 E PT 1019068E PT 97939108 T PT97939108 T PT 97939108T PT 97939108 T PT97939108 T PT 97939108T PT 1019068 E PT1019068 E PT 1019068E
Authority
PT
Portugal
Prior art keywords
neoplasms
prophylaxis
therapy
formulations containing
therapeutic formulations
Prior art date
Application number
PT97939108T
Other languages
English (en)
Inventor
Elizabeth Shanahan-Prendergast
Original Assignee
Elizabeth Shanahan-Prendergast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elizabeth Shanahan-Prendergast filed Critical Elizabeth Shanahan-Prendergast
Publication of PT1019068E publication Critical patent/PT1019068E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/58Reptiles
    • A61K35/583Snakes; Lizards, e.g. chameleons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/38Antigens from snakes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01004Phospholipase A2 (3.1.1.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/04Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04011Phosphoinositide phospholipase C (3.1.4.11)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
PT97939108T 1996-09-11 1997-09-10 Formulações terapêuticas contendo veneno de serpente e/ou insecto para a profilaxia e terapia de neoplasmas PT1019068E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2517996P 1996-09-11 1996-09-11

Publications (1)

Publication Number Publication Date
PT1019068E true PT1019068E (pt) 2009-10-08

Family

ID=21824505

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97939108T PT1019068E (pt) 1996-09-11 1997-09-10 Formulações terapêuticas contendo veneno de serpente e/ou insecto para a profilaxia e terapia de neoplasmas

Country Status (10)

Country Link
US (5) US20030175277A1 (pt)
EP (1) EP1019068B1 (pt)
AT (1) ATE435023T1 (pt)
AU (1) AU741943B2 (pt)
CA (1) CA2265631A1 (pt)
DE (1) DE69739482D1 (pt)
ES (1) ES2329529T3 (pt)
HK (1) HK1028545A1 (pt)
PT (1) PT1019068E (pt)
WO (1) WO1998010776A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4700193B2 (ja) * 1998-09-08 2011-06-15 バイオモレキュラー・プロダクツ・インコーポレーテッド 脂肪の腸吸収を増加させるための方法および組成物
AU1534900A (en) * 1998-11-12 2000-06-05 Analytica Ltd A method of treatment
ES2282256T3 (es) * 2000-05-26 2007-10-16 Symphogen A/S Anticuerpos policlonales recombinantes o purificados para tratar la alergia.
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
EP1379235B1 (en) * 2000-10-10 2006-12-20 University Of North Carolina At Chapel Hill Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers
EP1391207A1 (en) * 2001-04-24 2004-02-25 Luis Alberto Costa Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids
DE10330712A1 (de) * 2003-07-08 2005-01-27 Toximed Gmbh Pharmarzeutischer Wirkstoff gegen Kolonkarzinome und andere Tumorarten
DE10342747A1 (de) * 2003-09-16 2005-04-28 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Melanome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189471A (en) 1978-07-11 1980-02-19 Merck & Co., Inc. Immunologic glycolipid adjuvants
EP0064366A1 (en) 1981-04-29 1982-11-10 Beecham Group Plc Pharmaceutical compositions
DE3784768T2 (de) * 1986-05-19 1993-06-24 Ventech Research Inc Verwendung von zusammensetzungen auf basis von crotoxin, zur herstellung von medikamenten zur behandlung von carcinomen.
US5053492A (en) * 1986-08-07 1991-10-01 Board Of Regents, The University Of Texas System Immunopurification using monoclonal antibodies to Mojave toxin
US5164196A (en) * 1987-05-19 1992-11-17 Ventech Research, Inc. Crotoxin complex as cytotoxic agent
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
US4822608A (en) * 1987-09-14 1989-04-18 Vespa Laboratories, Inc. Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom or proteinaceous or polypeptide components thereof
FR2623508B1 (fr) * 1987-11-20 1990-04-20 Commissariat Energie Atomique Proteine basique denommee phospholipase a2 isolee de venin de serpent de la famille des elapides et sa sequence en amino-acides, derives et fragments de ladite proteine, leur procede d'obtention, compositions therapeutiques et agents de diagnostic contenant ladite proteine et/ou ses derives et/ou ses fragments
US5622832A (en) * 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
JP2984029B2 (ja) * 1990-05-30 1999-11-29 塩野義製薬株式会社 膜型ホスホリパーゼa▲下2▼を認識するモノクローナル抗体および膜型ホスホリパーゼa▲下2▼の免疫測定法
US5178864A (en) * 1990-08-14 1993-01-12 Mit Lipoprotein removal by soluble enzymes
DE4142552A1 (de) * 1991-12-21 1993-06-24 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen die typ i phospholipase a(pfeil abwaerts)2(pfeil abwaerts) als entzuendungshemmendes therapeutikum
US5565431A (en) * 1994-06-20 1996-10-15 Lipps; Binie V. Cancer cell inhibitors and method
FR2722692B1 (fr) 1994-07-20 1997-03-21 Rhone Poulenc Rorer Sa Medicament a base de phospholipase a2 de venin d'abeille
US5698583A (en) * 1994-11-15 1997-12-16 Crescenti; Ernesto J.V. Oligoelements and phospholipase A2 immuno-enhancer compositions, preparation thereof, and use thereof

Also Published As

Publication number Publication date
ES2329529T3 (es) 2009-11-26
DE69739482D1 (de) 2009-08-13
US20120258115A1 (en) 2012-10-11
HK1028545A1 (en) 2001-02-23
US20080044431A1 (en) 2008-02-21
CA2265631A1 (en) 1998-03-19
WO1998010776A1 (en) 1998-03-19
EP1019068A1 (en) 2000-07-19
US8580744B2 (en) 2013-11-12
US20030175277A1 (en) 2003-09-18
US20100196459A1 (en) 2010-08-05
EP1019068B1 (en) 2009-07-01
ATE435023T1 (de) 2009-07-15
AU741943B2 (en) 2001-12-13
AU4132397A (en) 1998-04-02
US20040131632A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AU2431995A (en) Method for reduction of headache pain
AU549481B2 (en) Hair growing agent
MY119375A (en) Treatment of tinnitus using neuroprotective agents
IT1283102B1 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
UA41355C2 (uk) Засіб для лікування нейро-сніду
ID19520A (id) Formulasi-formulasi aerosol untuk pengobatan yang mengandung formoterol
MX9401294A (es) Derivados de azolona sustituida
EP0746313A4 (en) METHOD FOR TREATING SMALL Mouth Ulcers
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
HK1028545A1 (en) Therapeutic formulations containing snake and/or insect venom for the prophylaxis and therapy of neoplasms
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
AU3474593A (en) Hypericin treatment of vaccine agents for improved immunogenicity
IL123001A0 (en) Analgesic from snake venom
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
IT1293583B1 (it) Uso dell'acido gammaidrossibutirrico per il trattamento delle sindromi demenziali
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
AU4261399A (en) Use of crataegus formulations for prophylaxis and treatment of neoplastic diseases
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
ES2170377T3 (es) Composicion que contiene quitosana.
MX9304056A (es) Compuestos para el tratamiento de padecimientos neoplasticos.
IS6017A (is) Aðferð til meðhöndlunar á höfuðverk
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION